Halozyme Therapeutics clinical trials
The registry lists 42 studies whose lead sponsor is Halozyme Therapeutics or the company grouped under it. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 42studies on the registry
- 1open to participants now
- 1phase 3 study under way
Get an email when these change. Save the Halozyme Therapeutics studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Halozyme Therapeutics’ studies test, most open studies first — 10 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- Testosterone3 in phase 31 open · 5
- testosterone enanthate1 in phase 31 open · 1
- hyaluronidase (human recombinant)1 in phase 30 open · 20
- 0 open · 7
- 0 open · 7
- 0 open · 3
- 0 open · 2
- 0 open · 1
- 0 open · 1
- oxybutynin1 in phase 30 open · 1
All 42 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 709
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 4 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Halozyme Therapeutics.
- Halozyme Therapeutics33 studiesSame company
Something wrong?
- Antares Pharma Inc.9 studies →Acquired — became part of Halozyme Therapeutics, May 24, 2022 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismRecruitingNCT06689085Phase 3
- Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact DermatitisCompletedNCT00928447Phase 2
- Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder CancerCompletedNCT00318643Phase 1/2
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerCompletedNCT01839487Phase 2
- A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaTerminatedNCT02715804Phase 3
- Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder AdenocarcinomaTerminatedNCT03267940Phase 1
- A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid TumorsCompletedNCT02563548Phase 1
- Pharmacokinetic Study of Subcutaneous Testosterone EnanthateCompletedNCT02233751Phase 1
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20CompletedNCT00705536Phase 1
- Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes MellitusCompletedNCT00774800Phase 2
- Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human HyaluronidaseCompletedNCT01526733Phase 4
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusCompletedNCT01194245Phase 2
- A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCTerminatedNCT02346370Phase 1
- A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)CompletedNCT03662334Phase 4
- Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic CancerCompletedNCT01453153Phase 1/2
- Subcutaneous Rehydration Compared to Intravenous RehydrationCompletedNCT00773175Phase 4
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01848990Phase 4
- Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)CompletedNCT00656370Phase 4
- Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20CompletedNCT00803972Phase 1
- Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate AloneCompletedNCT00807963Phase 1
- Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With HypogonadismCompletedNCT02504541Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Safety of Subcutaneous Testosterone Enanthate in Adult Male HypogonadismCompletedNCT02777242Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With HypogonadismCompletedNCT02159469Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Pharmacokinetic Study of Testosterone EnanthateCompletedNCT01887418Phase 1/2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes MellitusCompletedNCT00883558Phase 2
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusCompletedNCT01194258Phase 2
- Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedNCT00916357Phase 2
- Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT01275131Phase 1
- Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro AloneCompletedNCT00862849Phase 1
- A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs AloneCompletedNCT00979875Phase 1
- Study of Topically Administered Oxybutynin Gel in Patients With Urge IncontinenceCompletedNCT00909181Phase 3
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Comparison of Methotrexate (MTX) and the VIBEX™ MTX DeviceCompletedNCT01618968Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector DeviceCompletedNCT01618955Phase 2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Exposure Study Comparing 3 Routes of Methotrexate (MTX) AdministrationCompletedNCT01737944Phase 1/2
Sponsor listed in the registry: Antares Pharma Inc. · First submitted before Antares Pharma Inc. became part of Halozyme Therapeutics
- Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid TumorsCompletedNCT01170897Phase 1
- Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy VolunteersCompletedNCT01572012Phase 1
- Safety Study of PEGPH20 Given to Patients With Advanced Solid TumorsCompletedNCT00834704Phase 1
- A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human HyaluronidaseCompletedNCT00435604Phase 1
- Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder CancerCompletedNCT00782587Phase 1
- INFUSE Morphine StudyCompletedNCT00593281Phase 3
- Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human HyaluronidaseCompletedNCT00369187Phase 4
- A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer SubjectsCompletedNCT00311519Phase 4